Skip to content
DataLookout
Menu

Replexa+NCT07336381

Shortwave Diathermy In-home Treatment for Indianapolis VA-only Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy

StatusWithdrawn
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Withdrawn before enrolling Sponsor's reason: Funding issues Show 5 more changesShow less
    • Enrollment target: estimated 10 to confirmed 0
    • Eligibility criteria expanded, about 19 words
    • Primary completion date changed from estimate of Dec 31, 2027 to Sep 24, 2026
    • Start date changed from estimate of Jul 1, 2026 to Sep 24, 2026
    • Site contact updated
  2. Notable Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027v3 Show 4 more changesShow less
    • Start date: Dec 5, 2025 to Jul 1, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Site details revised
    • Study title expanded, about 2 words
  3. Notable Primary endpoint revisedv2
  4. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed

Endpoints

Primary

Compare baseline and post-treatment lower extremity arterial dopplers to determine change in lower extremity arterial perfusion.
Timeframe: 3 months

Secondary (1)

Identify the presence and role of inflammatory biomarkers in PAD.

Arms and interventions

InterventionExperimental

In-home shortwave diathermy treatment.

Devices: Replexa shortwave diathermy

Sites

1 site in 1 country

  • Richard L. Roudebush Veterans Affairs Medical CenterIndianapolis, Indiana, United States